In penning a response to one of its U.S. Senate critics, Mylan NV underscored the $1 billion it has spent over the past eight years to make people more aware of the risk of anaphylaxis and their need for drug-device products like the company's Epipen auto-injector, which happens to have the U.S. market for emergency treatment of life-threatening allergic reactions pretty much to itself right now.